

News Release

February 16, 2024

DBJ Capital Co., Ltd.

DBJ Capital Adopted for AMED's Strengthening Program for Pharmaceutical Startup Ecosystem

Japan Agency for Medical Research and Development (AMED) has selected DBJ Capital Co., Ltd. as a certified venture capital firm (VC) for its Strengthening Program for Pharmaceutical Startup Ecosystem (Note 1).

The program is intended to solve the shortage of funds for large-scale development and enhance the ecosystem of Japan's pharmaceutical startups. AMED selects and designates VCs providing hands-on commercialization support to pharmaceutical startups as part of the program. It then provides commercialization development support to pharmaceutical startups that are at the stages of non-clinical studies or Phase I, Phase II or exploratory clinical trials, on condition that the designated VCs will provide capital injection (Note 2).

DBJ Capital has made venture investments through DBJ Capital Fund (Note 3) and other means, with a mission to make a significant impact on the world, we continue striving to seek innovative technologies and businesses and take on challenges with entrepreneurs by providing long-term support and financing for startups.

With this designation, we will further upgrade our investments in and hands-on support for pharmaceutical startups.

Notes:

1. AMED: Selected proposals for the FY2023 (third round) Strengthening Program for Pharmaceutical Startup Ecosystem (see https://www.amed.go.jp/koubo/19/02/1902C_00045.html)

2. AMED: Strengthening Program for Pharmaceutical Startup Ecosystem (see <https://www.amed.go.jp/program/list/19/02/005.html>)

3. DBJ Capital Fund

Fund name	: DBJ Capital Investment Limited Partnership
Fund size	: 34.32 billion JPY
General Partner	: DBJ Capital Co., Ltd.
Limited Partner	: Development Bank of Japan Inc.